Generic Name: ledipasvir / sofosbuvir
Applies to ledipasvir / sofosbuvir: oral tablet
In addition to its needed effects, some unwanted effects may be caused by ledipasvir / sofosbuvir. In the event that any of these side effects do occur, they may require medical attention.
You should check with your doctor immediately if any of these side effects occur when taking ledipasvir / sofosbuvir:
Some of the side effects that can occur with ledipasvir / sofosbuvir may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:


Applies to ledipasvir / sofosbuvir: oral tablet
The most common side effects reported with this drug were fatigue and headache.  When this drug was studied with ribavirin, the most common side effects to this combination were consistent with known ribavirin side effects; frequency and severity of the expected side effects were not increased.  Therapy was permanently discontinued due to side effects in 0%, less than 1%, and 1% of patients using this drug for 8, 12, and 24 weeks, respectively, and less than 1%, 0%, and 2% for patients using this drug with ribavirin for 8, 12, and 24 weeks, respectively.The manufacturer product information for ribavirin should be consulted, if applicable.[Ref]
Very common (10% or more): Fatigue (up to 18%)[Ref]
Very common (10% or more): Headache (up to 17%)[Ref]
Common (1% to 10%): Nausea, diarrhea, increased lipase[Ref]
Increased lipase (greater than 3 times the upper limit of normal [3 x ULN]) was reported in less than 1%, 2%, and 3% of subjects using this drug for 8, 12, and 24 weeks, respectively.  Lipase elevation was transient and asymptomatic.[Ref]
Common (1% to 10%): Insomnia[Ref]
Increased bilirubin (greater than 1.5 x ULN) was reported in 3%, less than 1%, and 2% of subjects using this drug for 8, 12, and 24 weeks, respectively.[Ref]
Common (1% to 10%): Increased bilirubin[Ref]
Postmarketing reports: Serious symptomatic bradycardia (including fatal cardiac arrest, cases requiring pacemaker intervention)[Ref]
Serious symptomatic bradycardia has been reported in patients taking amiodarone who started therapy with this drug.[Ref]
Frequency not reported: Increased creatine kinase[Ref]
Creatine kinase was not evaluated in clinical trials for this drug.  Isolated, asymptomatic creatine kinase elevations (grade 3 or 4) were reported with sofosbuvir in combination with ribavirin or peginterferon alfa/ribavirin in other clinical trials.[Ref]
1. "Product Information. Harvoni (ledipasvir-sofosbuvir)." Gilead Sciences, Foster City, CA. 
2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0
3. FDA. U.S. Food and Drug Administration "FDA Drug Safety Communicaation: FDA warns of serious slowing of the heart rate when antiarrhythmic drug amiodarone is used with hepatitis C treatments containing sofosbuvir (Harvoni or Sovaldi) in combination with another Direct Acting Antiviral drug. Ava"   ([2015 Mar 24]):
Not all side effects for Harvoni may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

Chest pain or discomfort
lightheadedness, dizziness, or fainting
shortness of breath
slow or irregular heartbeat
unusual tiredness


Cough
diarrhea
headache
irritability
lack or loss of strength
muscle pain
nausea
trouble breathing
trouble sleeping
unusual tiredness or weakness


Discouragement
dizziness
feeling sad or empty
lack of appetite
loss of interest or pleasure
trouble concentrating

